EmendoBio has chosen VIVEbiotech as its partner for the development and subsequent manufacturing of lentiviral vectors in clinical quality.

EmendoBio, created in 2015 and with its headquarters in New York and research laboratories in Israel, develops gene therapies for diseases of genetic origin. They are currently developing programs for hematology, ophthalmology, dermatology and oncology.

VIVEbiotech will manufacture the batches for Emendo in its new facilities in San Sebastián, facilities that will allow us to increase innovation and manufacturing capabilities of specialist lentiviral vectors.